These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 34755408)

  • 1. Covid-19 vaccines and variants of concern: A review.
    Hadj Hassine I
    Rev Med Virol; 2022 Jul; 32(4):e2313. PubMed ID: 34755408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review.
    Fiolet T; Kherabi Y; MacDonald CJ; Ghosn J; Peiffer-Smadja N
    Clin Microbiol Infect; 2022 Feb; 28(2):202-221. PubMed ID: 34715347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
    Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
    J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking the COVID-19 vaccines: The global landscape.
    Yadav T; Kumar S; Mishra G; Saxena SK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
    Simões RSQ; Rodríguez-Lázaro D
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
    Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
    Rogliani P; Chetta A; Cazzola M; Calzetta L
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.